(Reuters) -Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized ...

We came across a bullish thesis on Gilead Sciences, Inc. on Dividend Talks’s Substack. In this article, we will summarize the ...

This was the stock's second consecutive day of gains.

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio. Bridgewater ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Gilead Sciences (NasdaqGS:GILD) recently announced a partnership with the Global Fund to supply lenacapavir for HIV ...

Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding ...

The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, ...

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

Gilead has partnered with Global Fund to supply lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP).

Shares of Gilead Sciences, Inc. GILD have gained 27.2% in the past six months against the industry’s decline of 2.2%. The ...

ETAGX - Eventide Gilead A - Review the ETAGX stock price, growth, performance, sustainability and more to help you make the best investments.